Loading...
ROCO
4743
Market cap809mUSD
Jul 09, Last price  
54.20TWD
1D
-2.69%
1Q
2.46%
Jan 2017
58.02%
IPO
30.41%
Name

Oneness Biotech Co Ltd

Chart & Performance

D1W1MN
ROCO:4743 chart
P/E
—
P/S
201.22
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.37%
Rev. gr., 5y
25.42%
Revenues
129m
+9.49%
1,631,00059,093,0003,715,0008,597,0004,609,0005,479,0007,841,0005,703,0002,587,00018,856,00013,475,00041,605,00065,765,0001,065,554,00086,783,000117,926,000129,122,999
Net income
-1.04b
L-10.33%
6,280,000953,00013,956,000-27,390,000276,253,000199,726,000-93,017,000-14,257,000-155,446,000-235,436,000-328,463,000-251,679,000-412,823,000359,975,000-1,312,867,000-1,165,147,000-1,044,772,999
CFO
-449m
L+29.91%
-102,299,000153,245,000-29,266,00024,153,000-89,262,000-150,980,000-142,345,000-108,540,000-165,268,000-5,123,000-213,252,000158,138,000-288,894,000-881,001,000-422,176,000-345,579,000-448,929,000
Dividend
Jun 16, 20230.1124 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Oneness Biotech Co., Ltd., headquartered in Taipei City, Taiwan, functions as a biopharmaceutical enterprise primarily dedicated to the discovery and advancement of novel therapeutic agents, in addition to selling pharmaceutical and health-related merchandise. The company's operations are divided into its New Drug Research and Development segment and its Agricultural Products Cultivation segment. Its advanced therapeutic candidate, ON101, is currently undergoing Phase III clinical trials for the treatment of chronic diabetic foot ulcers. Additionally, OB318, an experimental anti-cancer drug, is progressing through Phase I clinical evaluation. The company's development pipeline further includes FB704A, which has successfully concluded its Phase I clinical trial for addressing rheumatoid arthritis and systemic sclerosis. Furthermore, FB825 is currently in Phase II clinical trials, targeting conditions like atopic dermatitis, various allergic diseases, and asthma. In its earlier stages, FB918, a human monoclonal antibody aimed at allergic asthma, is undergoing pre-clinical development. Beyond its pharmaceutical endeavors, Oneness Biotech also oversees agricultural cultivation and trading activities, encompassing the distribution of farm produce. The company was established and began operations in 2008.
URL
https://www.onenessbio.com/tc/index.htm
IPO date
Jun 19, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT